Clinical Trials Logo

Stimulant Use Disorder clinical trials

View clinical trials related to Stimulant Use Disorder.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05546515 Recruiting - Opioid Use Disorder Clinical Trials

Suvorexant for Opioid/Stimulant Co-use

Start date: December 1, 2022
Phase: Phase 2
Study type: Interventional

This study will evaluate whether Suvorexant 20mg reduces drug use and craving, and improves sleep and stress among persons with co-occurring opioid use disorder and stimulant use disorder.

NCT ID: NCT05286879 Recruiting - Substance Abuse Clinical Trials

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

ACTION
Start date: March 31, 2022
Phase: N/A
Study type: Interventional

This is a 5-year Hybrid Type 1 Effectiveness-Implementation Randomized Control Trial (RCT) that compares two models of linking and retaining individuals recently released from justice involvement to the continuum of community-based HIV prevention and treatment, HCV treatment, STI treatment, and opioid use disorder (OUD) prevention and treatment, medication for opioid use disorder (MOUD) service cascades of care.

NCT ID: NCT04228276 Recruiting - Clinical trials for Substance-related Disorders

Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation

VA-StARTS
Start date: February 5, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rTMS)) for Veterans with stimulant use disorder (SUD). Despite the large public health burden imposed by SUD, there is currently no FDA-approved or widely recognized effective somatic treatment. rTMS may be a promising treatment option for SUD. In this study, we will demonstrate the feasibility of applying rTMS to Veterans with SUD, examine the efficacy of rTMS in the treatment of SUD, and explore biomarkers that may guide patient selection for rTMS treatment and predict treatment response.